The drug giant GlaxoSmithKline said Monday it will collaborate with Vir Biotechnology on experimental treatments and potentially, vaccines against the novel coronavirus.

As part of the deal, GlaxoSmithKline will invest $250 million in the San Francisco startup at a 10% premium to the company’s closing share price on March 27.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • It is great that Glaxo is doing this. Hopefully until this is completed we will continue to use plasma containing SARS-COV2 globulin antibodies from recovered patients to infuse into seriously ill Covid19 patients to help boost their chances of recovery. The FDA approved Red Cross to collect, type and bank plasma from recovered Covid19 patients to use for plasma infusion. This is being done in trials at a number of US hospitals with some success already. There is also a series of trials being conducted using Heparin and N-Acetylcysteine to alleviate lung dysfunction in serious Covid19 patients. These drugs have been used successfully to help patients with Cystic Fibrocis, Pneumonic Plague and other lung aliments. Hopefully they will help get Covid19 off intubation with positive pressure ventilation.

  • After transmission, it can take several days for the body to produce antibodies to a virus. That makes serological tests less useful than viral RNA tests for diagnosing someone with COVID-19.
    Does anyone considering wearing a mask?

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy